These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20219371)

  • 1. Discovery of a novel selective PPARgamma modulator from (-)-Cercosporamide derivatives.
    Furukawa A; Arita T; Satoh S; Wakabayashi K; Hayashi S; Matsui Y; Araki K; Kuroha M; Ohsumi J
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2095-8. PubMed ID: 20219371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituents at the naphthalene C3 position of (-)-Cercosporamide derivatives significantly affect the maximal efficacy as PPARγ partial agonists.
    Furukawa A; Arita T; Fukuzaki T; Satoh S; Mori M; Honda T; Matsui Y; Wakabayashi K; Hayashi S; Araki K; Ohsumi J
    Bioorg Med Chem Lett; 2012 Feb; 22(3):1348-51. PubMed ID: 22225641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of novel (-)-Cercosporamide derivatives as potent selective PPARγ modulators.
    Furukawa A; Arita T; Fukuzaki T; Mori M; Honda T; Satoh S; Matsui Y; Wakabayashi K; Hayashi S; Nakamura K; Araki K; Kuroha M; Tanaka J; Wakimoto S; Suzuki O; Ohsumi J
    Eur J Med Chem; 2012 Aug; 54():522-33. PubMed ID: 22727448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes.
    Ye YL; Zhou Z; Zou HJ; Shen Y; Xu TF; Tang J; Yin HZ; Chen ML; Leng Y; Shen JH
    Bioorg Med Chem; 2009 Aug; 17(15):5722-32. PubMed ID: 19574056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyridine-2-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
    Humphries PS; Almaden JV; Barnum SJ; Carlson TJ; Do QQ; Fraser JD; Hess M; Kim YH; Ogilvie KM; Sun S
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6116-9. PubMed ID: 16979341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
    ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
    Humphries PS; Bailey S; Almaden JV; Barnum SJ; Carlson TJ; Christie LC; Do QQ; Fraser JD; Hess M; Kellum J; Kim YH; McClellan GA; Ogilvie KM; Simmons BH; Skalitzky D; Sun S; Wilhite D; Zehnder LR
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6120-3. PubMed ID: 16973358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
    Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
    Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
    Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
    J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents.
    Itoh T; Murota I; Yoshikai K; Yamada S; Yamamoto K
    Bioorg Med Chem; 2006 Jan; 14(1):98-108. PubMed ID: 16198578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
    Lu IL; Huang CF; Peng YH; Lin YT; Hsieh HP; Chen CT; Lien TW; Lee HJ; Mahindroo N; Prakash E; Yueh A; Chen HY; Goparaju CM; Chen X; Liao CC; Chao YS; Hsu JT; Wu SY
    J Med Chem; 2006 May; 49(9):2703-12. PubMed ID: 16640330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists.
    Ahn JH; Shin MS; Jung SH; Kang SK; Kim KR; Rhee SD; Jung WH; Yang SD; Kim SJ; Woo JR; Lee JH; Cheon HG; Kim SS
    J Med Chem; 2006 Jul; 49(15):4781-4. PubMed ID: 16854085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
    Henry JR; Li Y; Warshawsky AM; Brozinick JT; Hawkins ED; Misener EA; Briere DA; Montrose-Rafizadeh C; Zink RW; Yumibe NP; Ajamie RT; Wilken B; Devanarayan V
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6293-7. PubMed ID: 17005393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and pharmacological evaluation of novel benzoylazole-based PPAR α/γ activators.
    Ushiroda K; Maruta K; Takazawa T; Nagano T; Taiji M; Kohno T; Sato Y; Horai S; Yanagi K; Nagata R
    Bioorg Med Chem Lett; 2011 Apr; 21(7):1978-82. PubMed ID: 21377875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design of potent retinoid X receptor alpha agonists.
    Haffner CD; Lenhard JM; Miller AB; McDougald DL; Dwornik K; Ittoop OR; Gampe RT; Xu HE; Blanchard S; Montana VG; Consler TG; Bledsoe RK; Ayscue A; Croom D
    J Med Chem; 2004 Apr; 47(8):2010-29. PubMed ID: 15056000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a new class of benzoylpyrrole-based PPARα/γ activators.
    Ushiroda K; Maruta K; Kitoh M; Iwai K; Nagamine J; Tsuchida A; Taiji M; Nagata R
    Bioorg Med Chem Lett; 2011 Jan; 21(1):220-4. PubMed ID: 21130649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
    Lin CH; Peng YH; Coumar MS; Chittimalla SK; Liao CC; Lyn PC; Huang CC; Lien TW; Lin WH; Hsu JT; Cheng JH; Chen X; Wu JS; Chao YS; Lee HJ; Juo CG; Wu SY; Hsieh HP
    J Med Chem; 2009 Apr; 52(8):2618-22. PubMed ID: 19301897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (-)-Cercosporamide derivatives as novel antihyperglycemic agents.
    Furukawa A; Arita T; Satoh S; Araki K; Kuroha M; Ohsumi J
    Bioorg Med Chem Lett; 2009 Feb; 19(3):724-6. PubMed ID: 19109017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.